RN7SL1 is typically shielded by RBP SRP9/14, but loss of these RBPs leads to inflammation and activation of its pattern recognition receptor, retinoic acid-inducible gene I (PRR RIG-I), leading to therapeutic resistance, tumor growth, and metastasis. Here, RIGI is linked to neoplasm.